The association of CYP2C19 metabolism status and side effects including hyperactivity, weight gain, gastrointestinal symptoms and insomnia was also investigated in pediatric patients prescribed escitalopram for anxiety or depressive disorders. Here, CYP2C19 is linked to depressive disorder.